Oxford Immunotec Global PLC (OXFD) Sees Large Volume Increase
Shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) saw strong trading volume on Friday . 81,232 shares traded hands during mid-day trading, an increase of 49% from the previous session’s volume of 54,426 shares.The stock last traded at $9.65 and had previously closed at $9.59.
Several equities research analysts recently commented on the company. Zacks Investment Research downgraded Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a report on Friday. BTIG Research reiterated a “buy” rating and issued a $17.00 price objective on shares of Oxford Immunotec Global PLC in a report on Tuesday, August 2nd. Finally, Piper Jaffray Cos. reiterated a “buy” rating on shares of Oxford Immunotec Global PLC in a report on Sunday, June 26th.
The stock’s 50 day moving average price is $8.83 and its 200-day moving average price is $9.77. The stock’s market capitalization is $218.24 million.
Oxford Immunotec Global PLC (NASDAQ:OXFD) last issued its earnings results on Tuesday, August 2nd. The company reported ($0.29) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.33) by $0.04. During the same quarter in the prior year, the company posted ($0.33) earnings per share. The firm earned $19.20 million during the quarter, compared to analysts’ expectations of $18.10 million. Oxford Immunotec Global PLC’s quarterly revenue was up 34.3% compared to the same quarter last year. Analysts anticipate that Oxford Immunotec Global PLC will post ($1.28) earnings per share for the current year.
Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.